H&O Biosis (H&O Biosis, CEO Park Jong-min and Hyun Ki-woong) announced on the 1st that it will pursue joint research with Germany’s Fraunhofer Institute to determine the immune substance activity of a natural product complex liver cancer anticancer drug under development.
This joint research is related to immune activation with the Fraunhofer Institute in Germany. Based on H&Obiosys’ research results over the past four years, the project was carried out to understand the strengthening of immunity, which is an essential characteristic of natural product combinations.
H&O Biosis was established in 2019 and announced the results of in-vitro cell experiments showing that it has an inhibitory effect on liver cancer cell death and proliferation for three types of liver cancer cell lines, including Huh7, and that it prevents liver cancer cell metastasis and inhibits the creation of new blood vessels. there is.
In animal experiments conducted based on these cell experiment results, the growth of liver cancer cells for the liver cancer cell line (Huh7) was reduced by about 50%, and no abnormalities were found in repeated toxicity animal tests for 2 weeks. By combining the results, the 2023 Science It was published in the journal Cancers.
Liver cancer is the cancer with the second highest number of deaths after lung cancer, with an incidence rate of more than 10% increasing in 2021 compared to the past 5 years. It is difficult to detect early and is known as a disease with a high mortality rate within 5 years when recurrence occurs.
Until now, liver cancer treatment has relied on physical treatments such as transarterial embolization, radiofrequency therapy, and liver transplantation. Bayer’s sorafenib (product name: Nexavar) has been developed and used, but is only effective in about 10% of Asians, where many liver cancer patients occur. Although it is known, its administration is limited due to severe side effects such as skin reactions on hands and feet, vomiting, and diarrhea due to toxicity. Therefore, as there are few treatments available, the development of anticancer drugs for liver cancer is an area that many companies are taking on.
Dr. Jong-min Park, CEO of H&O Biosis, said, “If the immune substance activation efficacy of HO-1197, a natural product composite liver cancer anticancer drug being developed in this study, is revealed, we expect to increase the possibility of developing a natural product composite liver cancer anticancer drug.” He added, “In particular, toxicity and side effects are minimized. Considering the characteristics of the natural product combination, we expect that it will not only increase the feasibility of conducting clinical trials in the future, but also help liver cancer patients who rely on painful physical treatment and anticancer drugs with severe side effects.”
He continued, “Based on this research, we aim to register additional papers and apply for IND in early 2025, and based on this, we plan to pursue phase 1 clinical trials. “In the meantime, we will grow into a leading company in the field of liver cancer anticancer drugs by breaking away from the image that ‘natural product combinations are adjuvant anticancer treatments’ and solidifying their status as full-fledged first-line treatments,” he added.
Choi Yong-seok, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-10-08 22:30:21